RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a $4.25 million private placement of preferred stock units. Each unit was priced at $7.00 and consisted of one share of PolyMedix convertible preferred stock and a five year warrant initially exercisable for one share of PolyMedix convertible preferred stock at $10.00 per share. Emerging Growth Equities Ltd. of King of Prussia, PA was the placement agent and Carter Securities of New York acted as a selected dealer in the private placement.
